Trial Outcomes & Findings for Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (NCT NCT06285240)

Results Overview

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

28 participants

Primary outcome timeframe

Up to approximately 7 weeks

Results posted on

2025-10-14

Participant Flow

All randomized participants

Participant milestones

Participant milestones
Measure	Panel A: MK-1167 + Donepezil 10mg QD Participants received 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD + Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days-3 to 31.
Overall Study STARTED	12	4	9	3
Overall Study Treated	12	4	9	3
Overall Study Panel A Participants Who Received 6mg of MK-1167	12	0	0	0
Overall Study Panel A Participants Who Received 3mg of MK-1167	12	0	0	0
Overall Study COMPLETED	10	4	8	3
Overall Study NOT COMPLETED	2	0	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Panel A: MK-1167 + Donepezil 10mg QD Participants received 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD + Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days-3 to 31.
Overall Study Withdrawal by Subject	2	0	0	0
Overall Study Serious Adverse Event	0	0	1	0

Baseline Characteristics

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Panel A: MK-1167 + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD n=4 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD + Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD n=3 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days-3 to 31.	Total n=28 Participants Total of all reporting groups
Age, Continuous	68.2 Years STANDARD_DEVIATION 8.2 • n=5 Participants	63.5 Years STANDARD_DEVIATION 8.7 • n=7 Participants	69.9 Years STANDARD_DEVIATION 8.6 • n=5 Participants	75.3 Years STANDARD_DEVIATION 2.9 • n=4 Participants	68.8 Years STANDARD_DEVIATION 8.2 • n=21 Participants
Sex: Female, Male Female	6 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	13 Participants n=21 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	1 Participants n=7 Participants	6 Participants n=5 Participants	2 Participants n=4 Participants	15 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	2 Participants n=4 Participants	12 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	8 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants	1 Participants n=4 Participants	16 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Black or African American	6 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	11 Participants n=21 Participants
Race (NIH/OMB) White	6 Participants n=5 Participants	2 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	17 Participants n=21 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants

PRIMARY outcome

Timeframe: Up to approximately 7 weeks

Population: All randomized participants who received at least one dose of study treatment.

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD n=12 Participants After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD n=4 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD n=3 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Number of Participants Who Experienced an Adverse Event (AE)	3 Participants	5 Participants	2 Participants	6 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to approximately 4 weeks

Population: All randomized participants who received at least one dose of study treatment.

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD n=12 Participants After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD n=4 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD n=3 Participants Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Number of Participants Who Discontinued Study Treatment Due to an AE	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167	2.17 μM*hour Interval 1.22 to 3.84	—	—	—	—

SECONDARY outcome

Timeframe: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: AUC0-24 After Administration of 3mg of MK-1167 Day 8	8.70 μM*hour Interval 4.95 to 15.3	—	—	—	—
Panel A: AUC0-24 After Administration of 3mg of MK-1167 Day 21	8.08 μM*hour Interval 4.56 to 14.3	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: AUC0-24 After Administration of 6mg of MK-1167 Day 1	2.48 μM*hour Interval 2.04 to 3.01	—	—	—	—
Panel B: AUC0-24 After Administration of 6mg of MK-1167 Day 23	22.2 μM*hour Interval 18.1 to 27.1	—	—	—	—
Panel B: AUC0-24 After Administration of 6mg of MK-1167 Day 31	22.9 μM*hour Interval 18.8 to 28.0	—	—	—	—

SECONDARY outcome

Timeframe: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167	0.129 μmol/Liter Interval 0.0731 to 0.228	—	—	—	—

SECONDARY outcome

Timeframe: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Cmax After Administration of 3mg of MK-1167 Day 8	0.434 μmol/Liter Interval 0.247 to 0.761	—	—	—	—
Panel A: Cmax After Administration of 3mg of MK-1167 Day 21	0.413 μmol/Liter Interval 0.234 to 0.729	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Cmax After Administration of 6mg of MK-1167 Day 1	0.145 μmol/Liter Interval 0.121 to 0.174	—	—	—	—
Panel B: Cmax After Administration of 6mg of MK-1167 Day 23	1.11 μmol/Liter Interval 0.919 to 1.35	—	—	—	—
Panel B: Cmax After Administration of 6mg of MK-1167 Day 31	1.14 μmol/Liter Interval 0.941 to 1.38	—	—	—	—

SECONDARY outcome

Timeframe: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167	0.0902 μmol/Liter Interval 0.05 to 0.163	—	—	—	—

SECONDARY outcome

Timeframe: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg MK-1167) and had at least one postdose data available for assessment.

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: C24 After Administration of 3mg of MK-1167 Day 8	0.362 μmol/Liter Interval 0.203 to 0.647	—	—	—	—
Panel A: C24 After Administration of 3mg of MK-1167 Day 21	0.313 μmol/Liter Interval 0.174 to 0.565	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: C24 After Administration of 6mg of MK-1167 Day 1	0.0917 μmol/Liter Interval 0.0731 to 0.115	—	—	—	—
Panel B: C24 After Administration of 6mg of MK-1167 Day 23	0.729 μmol/Liter Interval 0.576 to 0.922	—	—	—	—
Panel B: C24 After Administration of 6mg of MK-1167 Day 31	0.875 μmol/Liter Interval 0.691 to 1.11	—	—	—	—

SECONDARY outcome

Timeframe: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167	1.54 hours Interval 0.5 to 8.0	—	—	—	—

SECONDARY outcome

Timeframe: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Tmax After Administration of 3mg of MK-1167 Day 8	6.00 hours Interval 0.0 to 23.97	—	—	—	—
Panel A: Tmax After Administration of 3mg of MK-1167 Day 21	4.01 hours Interval 1.22 to 11.92	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=9 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Tmax After Administration of 6mg of MK-1167 Day 1	1.08 hours Interval 0.48 to 5.78	—	—	—	—
Panel B: Tmax After Administration of 6mg of MK-1167 Day 23	4.03 hours Interval 0.58 to 11.92	—	—	—	—
Panel B: Tmax After Administration of 6mg of MK-1167 Day 31	2.97 hours Interval 0.42 to 11.9	—	—	—	—

SECONDARY outcome

Timeframe: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167	0.879 Liter/hour Geometric Coefficient of Variation 166.9	—	—	—	—

SECONDARY outcome

Timeframe: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: CL/F After Administration of 6mg of MK-1167	0.606 Liter/hour Geometric Coefficient of Variation 32.3	—	—	—	—

SECONDARY outcome

Timeframe: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167	194 hours Geometric Coefficient of Variation 48.2	—	—	—	—

SECONDARY outcome

Timeframe: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: t1/2 After Administration of 6mg of MK-1167	193 hour Geometric Coefficient of Variation 40.4	—	—	—	—

SECONDARY outcome

Timeframe: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel A randomized participants who received at least one dose of study treatment (3mg of MK-1167) and had at least one postdose data available for assessment.

Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=10 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167	246 Liter Geometric Coefficient of Variation 166.6	—	—	—	—

SECONDARY outcome

Timeframe: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment (6mg of MK-1167) and had at least one postdose data available for assessment.

Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Vz/F After Administration of 6mg of MK-1167	169 Liter Geometric Coefficient of Variation 19.7	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had AUC0-24 data available for assessment on Day 1 and Day 23.

Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167	8.95 Ratio Interval 7.8 to 10.27	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had AUC0-24 data available for assessment on Day 1 and Day 31.

Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167	9.26 Ratio Interval 8.08 to 10.62	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had at Cmax data available for assessment on Day 1 and Day 23.

Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167	7.69 Ratio Interval 6.46 to 9.16	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had at Cmax data available for assessment on Day 1 and Day 31.

Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167	7.88 Ratio Interval 6.62 to 9.38	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had C24 data available for assessment on Day 1 and Day 23.

Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167	7.94 Ratio Interval 6.64 to 9.5	—	—	—	—

SECONDARY outcome

Timeframe: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

Population: All Panel B randomized participants who received at least one dose of study treatment and had C24 data available for assessment on Day 1 and Day 31.

Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24.

Outcome measures

Outcome measures
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=8 Participants Participants received 6mg MK-1167 oral loading doses QD Days 1 to 7. Participants also receive 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD+ Donepezil 10mg QD Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days -3 to 31.
Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167	9.54 Ratio Interval 7.97 to 11.4	—	—	—	—

Adverse Events

Panel A: MK-1167 6mg QD + Donepezil 10mg QD

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Panel A: MK-1167 3mg QD + Donepezil 10mg QD

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Panel A: Placebo to MK-1167 + Donepezil 10mg QD

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Panel B: MK-1167 6mg QD + Donepezil 10mg QD

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

Panel B: Placebo to MK-1167 + Donepezil 10mg QD

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 participants at risk Participants received 6mg MK-1167 oral loading doses QD Days 1to 7. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD n=12 participants at risk After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD n=4 participants at risk Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD + Donepezil 10mg QD n=9 participants at risk Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD n=3 participants at risk Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days-3 to 31.
Vascular disorders Deep vein thrombosis	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.

Other adverse events

Other adverse events
Measure	Panel A: MK-1167 6mg QD + Donepezil 10mg QD n=12 participants at risk Participants received 6mg MK-1167 oral loading doses QD Days 1to 7. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: MK-1167 3mg QD + Donepezil 10mg QD n=12 participants at risk After an oral loading dose of 6mg MK-1167, participants received oral maintenance dose of 3mg MK-1167 QD Days 8 to 21. Participants also received 10mg oral Donepezil on Days -3 to 21.	Panel A: Placebo to MK-1167 + Donepezil 10mg QD n=4 participants at risk Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also received 10mg oral Donepezil QD on Days-3 to 21.	Panel B: MK-1167 6mg QD + Donepezil 10mg QD n=9 participants at risk Participants received 6mg MK-1167 oral doses QD Days 1 to 31. Participants also received 10mg oral Donepezil on Days -3 to 31.	Panel B: Placebo to MK-1167 + Donepezil 10mg QD n=3 participants at risk Participants received dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also received 10mg oral Donepezil QD on Days-3 to 31.
Cardiac disorders Supraventricular extrasystoles	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Ear and labyrinth disorders Ear pain	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Gastrointestinal disorders Constipation	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Gastrointestinal disorders Diarrhoea	16.7% 2/12 • Number of events 2 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Gastrointestinal disorders Nausea	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Gastrointestinal disorders Toothache	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Gastrointestinal disorders Vomiting	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
General disorders Chills	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
General disorders Malaise	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
General disorders Pyrexia	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Immune system disorders Seasonal allergy	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Infections and infestations Upper respiratory tract infection	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	22.2% 2/9 • Number of events 2 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Investigations Electrocardiogram PR prolongation	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Investigations Haemoglobin decreased	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Nervous system disorders Dizziness	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	25.0% 1/4 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Nervous system disorders Headache	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Nervous system disorders Tremor	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Psychiatric disorders Insomnia	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Psychiatric disorders Irritability	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	25.0% 1/4 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	25.0% 1/4 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Vascular disorders Hypertension	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	11.1% 1/9 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Vascular disorders Hypotension	8.3% 1/12 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/4 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Vascular disorders Orthostatic hypotension	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	25.0% 1/4 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.
Vascular disorders Pallor	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/12 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	25.0% 1/4 • Number of events 1 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/9 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.	0.00% 0/3 • Up to approximately 25 weeks All-Cause Mortality includes all randomized participants. Serious and Other adverse events (AEs) include all randomized participants who received ≥1 dose of study drug. Per protocol, Panel A: Placebo to MK-1167 + Donepezil 10mg QD arm was reported combined as dose matched placebo.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme LLC

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The results of this study may be published or presented at scientific meetings. The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Any information identified by the Sponsor as confidential must be deleted prior to submission.
Publication restrictions are in place

Restriction type: OTHER